Overview

Effectiveness of Colchicine Among Patients With COVID-19 Infection

Status:
Completed

Trial end date:
2021-06-18

Target enrollment:
0

Participant gender:
All

Summary

In November 2019, there were a lot of cases of an acute respiratory illness (then named at February 11th as COVID_19) which first case was reported in Wuhan, China,The SARS COV-2 had been spread in a fast way to involve whole world, As it's obvious that Colchicine is a drug that is most commonly and widely used to treat and prevent acute attacks of Gout, other crystal induced arthropathy,colchicine has important role in inhibiting activation of NLRP3 inflammasome these lead to decrease cytokine production , aim of study To evaluate whether colchicine is effective in the treatment of COVID-19 cases. And to measure the effectiveness of colchicine in alleviating and controlling pulmonary and extra pulmonary complications of COVID-19

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hawler Medical University

Treatments:

Colchicine

Criteria

Inclusion Criteria:

1.patients diagnosed clinically or by RT-PCR in nasopharyngeal swab specimens and/ or lung
involvement confirm by computed tomography scan compatible with COVID-19patients 2.Age
between 18 year and 70 years, 3.body weight > 50 kg, 4.with written informed consent from
patients or relatives.

-

Exclusion Criteria 1 sensitivity to any medications of regimens, 2.e GFR less than 30.
3.pregnancy. 4.malignancy . 5.Participating in another clinical study and refusing to
participate in the study at a later date or later, and they are already taking colchicine
for other diseases .

-